메뉴 건너뛰기




Volumn 3, Issue 1, 2017, Pages 10-22

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

Author keywords

Active immunotherapy; Alzheimer's disease; Amyloid beta peptides; Biological biomarkers; CAD106; Safety

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; MIFAMURTIDE; PLACEBO;

EID: 85012299260     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.12.003     Document Type: Article
Times cited : (113)

References (15)
  • 1
    • 20944448555 scopus 로고    scopus 로고
    • Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
    • [1] Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005), 1553–1562.
    • (2005) Neurology , vol.64 , pp. 1553-1562
    • Gilman, S.1    Koller, M.2    Black, R.S.3    Jenkins, L.4    Griffith, S.G.5    Fox, N.C.6
  • 2
    • 10744230547 scopus 로고    scopus 로고
    • Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
    • [2] Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003), 46–54.
    • (2003) Neurology , vol.61 , pp. 46-54
    • Orgogozo, J.M.1    Gilman, S.2    Dartigues, J.F.3    Laurent, B.4    Puel, M.5    Kirby, L.C.6
  • 3
    • 0037384333 scopus 로고    scopus 로고
    • Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
    • [3] Cribbs, D.H., Ghochikyan, A., Vasilevko, V., Tran, M., Petrushina, I., Sadzikava, N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15 (2003), 505–514.
    • (2003) Int Immunol , vol.15 , pp. 505-514
    • Cribbs, D.H.1    Ghochikyan, A.2    Vasilevko, V.3    Tran, M.4    Petrushina, I.5    Sadzikava, N.6
  • 5
    • 77951086901 scopus 로고    scopus 로고
    • Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    • [5] Siemers, E.R., Friedrich, S., Dean, R.A., Gonzales, C.R., Farlow, M.R., Paul, S.M., et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33 (2010), 67–73.
    • (2010) Clin Neuropharmacol , vol.33 , pp. 67-73
    • Siemers, E.R.1    Friedrich, S.2    Dean, R.A.3    Gonzales, C.R.4    Farlow, M.R.5    Paul, S.M.6
  • 7
    • 84892695519 scopus 로고    scopus 로고
    • Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
    • [7] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
    • (2014) N Engl J Med , vol.370 , pp. 322-333
    • Salloway, S.1    Sperling, R.2    Fox, N.C.3    Blennow, K.4    Klunk, W.5    Raskind, M.6
  • 8
    • 84892748542 scopus 로고    scopus 로고
    • Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
    • [8] Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
    • (2014) N Engl J Med , vol.370 , pp. 311-321
    • Doody, R.S.1    Thomas, R.G.2    Farlow, M.3    Iwatsubo, T.4    Vellas, B.5    Joffe, S.6
  • 9
    • 84862331908 scopus 로고    scopus 로고
    • Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
    • [9] Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11 (2012), 597–604.
    • (2012) Lancet Neurol , vol.11 , pp. 597-604
    • Winblad, B.1    Andreasen, N.2    Minthon, L.3    Floesser, A.4    Imbert, G.5    Dumortier, T.6
  • 10
    • 79959670013 scopus 로고    scopus 로고
    • The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
    • [10] Wiessner, C., Wiederhold, K.H., Tissot, A.C., Frey, P., Danner, S., Jacobson, L.H., et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31 (2011), 9323–9331.
    • (2011) J Neurosci , vol.31 , pp. 9323-9331
    • Wiessner, C.1    Wiederhold, K.H.2    Tissot, A.C.3    Frey, P.4    Danner, S.5    Jacobson, L.H.6
  • 12
    • 10744227803 scopus 로고    scopus 로고
    • Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells
    • [12] Karlsson, A.C., Martin, J.N., Younger, S.R., Bredt, B.M., Epling, L., Ronquillo, R., et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 283 (2003), 141–153.
    • (2003) J Immunol Methods , vol.283 , pp. 141-153
    • Karlsson, A.C.1    Martin, J.N.2    Younger, S.R.3    Bredt, B.M.4    Epling, L.5    Ronquillo, R.6
  • 13
    • 84858591462 scopus 로고    scopus 로고
    • Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects
    • [13] Joshi, A.D., Pontecorvo, M.J., Clark, C.M., Carpenter, A.P., Jennings, D.L., Sadowsky, C.H., et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 53 (2012), 378–384.
    • (2012) J Nucl Med , vol.53 , pp. 378-384
    • Joshi, A.D.1    Pontecorvo, M.J.2    Clark, C.M.3    Carpenter, A.P.4    Jennings, D.L.5    Sadowsky, C.H.6
  • 14
    • 0037205207 scopus 로고    scopus 로고
    • Aluminum salts in vaccines—US perspective
    • [14] Baylor, N.W., Egan, W., Richman, P., Aluminum salts in vaccines—US perspective. Vaccine 20 (2002), S18–S23.
    • (2002) Vaccine , vol.20 , pp. S18-S23
    • Baylor, N.W.1    Egan, W.2    Richman, P.3
  • 15
    • 18144415471 scopus 로고    scopus 로고
    • Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
    • [15] Fox, N.C., Black, R.S., Gilman, S., Rossor, M.N., Griffith, S.G., Jenkins, L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005), 1563–1572.
    • (2005) Neurology , vol.64 , pp. 1563-1572
    • Fox, N.C.1    Black, R.S.2    Gilman, S.3    Rossor, M.N.4    Griffith, S.G.5    Jenkins, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.